Does short dipyridamole administration induce protection against ischemia-reperfusion injury?

Phase 4

• Conditions: infarction; ischemia reperfusion injury; 10011082; 10003216

• Registration Number: NL-OMON31190
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

male
age 18-50 years

Exclusion Criteria

-cardiovascular disease
-hypertension (systole > 140 mmHg, diastole > 90 mmHg)
-hypercholesterolemia (fasting total cholesterol > 5.5 mmol/l or not fasting total cholesterol > 6.5mmol/L)
-diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
-asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
-participation in any clinical drug trial during the last 60 days prior to this study.
-administration of any radioactivity for research purposes during the last 5 years prior to this study.
-concomittant medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Percentage difference in radioactivity (counts/pixel) between experimental and<br /><br>control thenar muscle at 60 and 240 minutes after reperfusion.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>nvt</p><br>